Specializes in the research, development, and commercialization of prescription ophthalmic pharmaceuticals.
Alimera Sciences, Inc. is a pharmaceutical company specializing in the development and global distribution of ophthalmic pharmaceuticals. Headquartered in Alpharetta, Georgia, the company focuses on addressing critical eye conditions through innovative treatments. One of its flagship products, ILUVIEN, is an intravitreal implant designed to treat diabetic macular edema (DME), a condition that can lead to severe vision loss and blindness among diabetic patients. ILUVIEN also serves to prevent relapses in recurrent non-infectious uveitis affecting the posterior segment of the eye.
Established in 2003, Alimera Sciences markets its products directly to physician offices, pharmacies, and hospitals, utilizing both direct sales channels and strategic distributor partnerships. The company's commitment to advancing eye care extends through collaborative efforts, including a significant partnership with EyePoint Pharmaceuticals US, Inc. This collaboration focuses on developing insert technology to deliver corticosteroids effectively to the posterior segment of the eye, targeting various eye diseases including diabetic macular edema.
Driven by a dedication to innovation and patient care, Alimera Sciences continues to expand its portfolio and geographical reach. With a strong emphasis on research and development, the company remains at the forefront of ophthalmic pharmaceuticals, striving to improve the quality of life for individuals affected by serious eye conditions worldwide.